by European Public Health Alliance | Nov 9, 2022 | #A2Medicines
Enhancing patients’ access to high-quality and affordable medicinal products across the European Union while preserving the financial sustainability of healthcare systems should be the overarching aim of the current revision of the general pharmaceutical legislation....
by European Public Health Alliance | Oct 28, 2022 | #A2Medicines
By Benedetta Baldini, Health Policy Lead at the European Social Insurance Platform (ESIP) Solidarity. This defining principle of social protection across Europe is what makes our welfare systems citizen-centred and society-conscious. Applied to the healthcare sector,...
by European Public Health Alliance | Oct 28, 2022 | #A2Medicines, COVID-19
By Tom Buis, Global Health Advocate at Wemos Now more than ever is the time to advocate together for structural solutions to achieve equitable access to medical products. In the upcoming months, member states of the World Health Organization (WHO) will start the...
by European Public Health Alliance | Oct 28, 2022 | #A2Medicines
By Stephanie Kohl, Policy & Advocacy Officer at the European Association of Hospital Pharmacists (EAHP) Providing equal and timely access for all patients, including those with rare conditions and unmet needs, to all relevant medicinal therapies is one of the...
by European Public Health Alliance | Oct 28, 2022 | #A2Medicines
By Dr Ward Rommel, Chair, Access to Medicines Task Force, Association of European Cancer Leagues (ECL) – @CancerLeagues & @WardRommel | #LetsTalkAccess If you have cancer and you need medicine, you should be able to get it. Everyone agrees but, sadly,...
by European Public Health Alliance | Oct 28, 2022 | #A2Medicines
In June 2022, the members of the European Alliance for Responsible R&D and Affordable Medicines gathered in Rome to analyse the current public health scene and discuss potential solutions to the most prominent challenges. In light of public health outbreaks in the...
